Intrarosa and Alcohol: What Women Need to Know About This Interaction

Does Alcohol Interact with Intrarosa?

No interaction between alcohol and prasterone vaginal inserts appears in the FDA-approved Intrarosa prescribing information. The label's drug interaction section focuses on cytochrome P450 metabolism, and prasterone's vaginal-to-systemic conversion is modest enough that a clinically significant pharmacokinetic collision with alcohol has not been identified in phase III studies.

That does not mean alcohol is entirely irrelevant. Alcohol and sex hormones interact at the metabolic level, and because Intrarosa works by converting DHEA into locally active estradiol and testosterone inside vaginal epithelial cells, anything that shifts estrogen metabolism in your body can theoretically affect the drug's hormonal milieu. The effect is small with low-to-moderate alcohol intake, but it is worth understanding precisely.

Why the Interaction Risk Is Lower Than with Oral Hormone Therapy

Oral estradiol undergoes substantial first-pass hepatic metabolism. Alcohol inhibits CYP3A4 and alcohol dehydrogenase pathways that clear estradiol, so drinking while on oral estrogen can meaningfully raise circulating estradiol. Intrarosa bypasses first-pass metabolism almost entirely. Phase I pharmacokinetic data submitted to the FDA showed that after a single 6.5 mg vaginal insert, peak serum DHEA reached roughly 9.9 ng/mL and serum estradiol rose to approximately 8-10 pg/mL, which falls within the normal postmenopausal reference range of 5-20 pg/mL. The systemic estrogen load is simply smaller than with oral or transdermal estradiol, so alcohol's inhibition of hepatic clearance produces a correspondingly smaller absolute effect.

What Alcohol Does Do to Your Hormones

Even without a labeled interaction, alcohol changes the hormonal environment in ways relevant to GSM and menopause management.

• Alcohol inhibits hepatic oxidation of estradiol, raising circulating estrogen transiently. A 1996 NEJM study by Ginsburg et al. showed that a single drink raised estradiol by 300% in postmenopausal women on oral hormone replacement. The magnitude with vaginal prasterone would be smaller, but the direction is the same.
• Chronic heavy alcohol use suppresses DHEA sulfate (DHEAS) production from the adrenal glands. Because prasterone is exogenous DHEA, this adrenal suppression does not cancel the drug's local action, but it does mean women who drink heavily may have a different baseline hormonal picture.
• Alcohol disrupts sleep architecture. GSM symptoms, including nocturia and discomfort-driven waking, are already common in postmenopausal women, and alcohol-impaired sleep can make it harder to assess whether Intrarosa is working.

How Prasterone Works: The Intracrinology Matters

Understanding why alcohol matters (or doesn't) requires a brief look at how unusual this drug is.

Prasterone is the synthetic version of DHEA, the adrenal steroid that serves as the precursor to both estrogen and testosterone. When the 6.5 mg insert dissolves in the vagina overnight, the DHEA is taken up by vaginal epithelial cells and converted locally into estradiol and testosterone by enzymes within those cells. This is called intracrinology: the target tissue makes its own hormones from a precursor, regulates how much it makes, and the hormones act locally without being released back into circulation in large quantities.

The REJOICE trial, the key phase III study published in Menopause in 2016, enrolled 325 women and confirmed that once-nightly prasterone 6.5 mg significantly improved the percentage of superficial cells, parabasal cells, vaginal pH, and the most bothersome symptom of dyspareunia compared with placebo. Circulating estradiol in treated women remained within postmenopausal range throughout the 12-week trial. Systemic hormonal exposure was the key safety question, and the data reassured regulators.

Because the conversion happens inside the vaginal wall rather than in the liver, the hepatic enzyme effects that alcohol exerts on oral estrogen metabolism are buffered. Alcohol does not sit at the same metabolic chokepoint for vaginally delivered DHEA as it does for a swallowed estradiol pill.

Sex-Specific Physiology: How Female Hormonal Status Changes the Picture

Clinicians discussing hormone-drug interactions with women must think across life stages, because the hormonal context changes the meaning of "modest systemic estradiol."

Postmenopause (the primary Intrarosa population)

Postmenopausal women have endogenous estradiol levels typically below 20 pg/mL. The systemic estradiol from one nightly Intrarosa insert adds to that baseline, and alcohol's transient inhibition of estradiol clearance adds a small further increment. For most women drinking one standard drink (14 g ethanol), the combined effect is clinically insignificant. Women who drink three or more standard drinks in an evening, however, may see a more sustained elevation of circulating estradiol because liver clearance is more substantially inhibited at higher alcohol doses. For postmenopausal women with a personal or strong family history of estrogen-receptor-positive breast cancer, that increment, however small, is worth discussing with a clinician before combining regular alcohol use with any estrogen-raising therapy.

The Menopause Society (formerly NAMS) 2022 position statement on hormone therapy acknowledges that breast cancer risk from systemic hormone therapy is a complex, dose- and duration-dependent issue. Locally applied prasterone with its low systemic estrogen exposure is considered a lower systemic risk profile, but combining it with regular alcohol use has not been studied in a randomized trial.

Perimenopause

Intrarosa is not FDA-approved for perimenopausal women, who by definition still have menstrual cycles and higher, more variable endogenous estradiol. GSM symptoms can begin in late perimenopause, and some clinicians prescribe prasterone off-label at this stage. If you are perimenopausal and using Intrarosa, alcohol's interaction with your already-fluctuating estradiol is less predictable, and reliable contraception is critical (see the pregnancy section below).

Trying to Conceive

DHEA supplementation has been studied as an adjunct to IVF in poor ovarian responders. That is oral DHEA at much higher doses, not vaginal prasterone, and these are entirely different clinical contexts. Vaginal prasterone is not indicated for fertility use. If you are trying to conceive, see the contraindication section that follows.

Pregnancy and Lactation Safety (Required Reading Before Starting Intrarosa)

Prasterone vaginal inserts are contraindicated in pregnancy. This is stated explicitly in the Intrarosa prescribing label. DHEA and its estrogenic and androgenic metabolites can affect fetal development. No adequate human pregnancy data exist because the drug should never be used during pregnancy.

Pregnancy Category and Human Data

The FDA pregnancy category system was replaced in 2015 by the Pregnancy and Lactation Labeling Rule (PLLR). Under the current label, the reproductive section states that animal reproductive studies are not always predictive of human response and that the drug should be avoided in pregnancy. Given that endogenous DHEA is a precursor to androgens, even locally converted androgenic metabolites carry a theoretical risk of virilizing a female fetus.

If you are of reproductive age and a clinician is considering off-label prasterone for late-perimenopausal GSM, reliable contraception is required. You should not rely on the drug's local delivery as a reason to be less careful about pregnancy prevention.

Contraception Note

Prasterone is not a contraceptive. It does not suppress ovulation. Perimenopausal women who are still ovulating irregularly can still conceive, and an unintended pregnancy while using Intrarosa would require immediate discontinuation and urgent obstetric consultation.

Lactation

The prescribing label does not recommend Intrarosa during breastfeeding. DHEA and its metabolites, including estradiol and testosterone, may be present in breast milk, though the extent of transfer from the vaginal route at low systemic levels has not been formally quantified in lactation studies. The absence of data, combined with the drug's androgenic metabolite profile, means the conservative clinical recommendation is to avoid use during lactation.

Alcohol, Sleep, and GSM Symptoms: A Practical Triangle

Intrarosa is inserted at bedtime. You insert it, go to sleep, and the DHEA absorbs and works during the hours you are asleep. Alcohol at bedtime impairs REM sleep and increases nighttime waking, which is already common in postmenopausal women due to vasomotor symptoms and GSM-related discomfort.

The Study of Women's Health Across the Nation (SWAN) documented that sleep disturbance in midlife women is strongly associated with vasomotor symptoms and urogenital changes. Alcohol, even one drink, has been shown in polysomnographic studies to reduce REM sleep in the second half of the night. If you are using Intrarosa primarily for painful intercourse and also struggling with sleep, nightly alcohol use can compound the sleep disruption and make it harder to evaluate the drug's benefit.

Practically: inserting Intrarosa and then drinking a glass of wine before bed is not dangerous, but it is counterproductive if your goal is optimal treatment response and good sleep.

Drug-Drug Interactions Beyond Alcohol: What the Label Actually Lists

The Intrarosa prescribing information identifies several metabolic cautions that apply independently of alcohol.

Prasterone is metabolized by CYP3A4, CYP3A5, and several other isoforms. In theory, potent CYP3A4 inhibitors (such as ketoconazole, clarithromycin, or grapefruit in large quantities) could increase systemic DHEA or metabolite exposure. Potent CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort) could reduce local conversion efficacy.

Alcohol is a weak, acute inhibitor of CYP3A4 at high concentrations. At one to two standard drinks, the inhibition is modest. At binge-level intake (four or more drinks), the CYP3A4 inhibition is more sustained and could in principle raise systemic DHEA metabolites transiently. This is pharmacokinetic extrapolation, not a studied interaction, and the clinical relevance at the low systemic exposure levels seen with vaginal prasterone is likely small.

Women on tamoxifen for breast cancer risk reduction or treatment should discuss any vaginal estrogen or DHEA-based product with their oncologist, because even low systemic estrogenic activity is subject to oncology team review. The ACOG Clinical Guidance on Genitourinary Syndrome of Menopause (2023) notes that vaginal prasterone is generally considered low systemic exposure, but that hormone-sensitive cancer history warrants individualized discussion.

Who Intrarosa Is Right For (and Who Should Be Cautious)

Women most likely to benefit

• Postmenopausal women with moderate-to-severe dyspareunia due to GSM who prefer non-systemic or locally acting therapy
• Women who cannot or prefer not to use systemic estrogen for reasons including cardiovascular history, migraines with aura, or personal preference
• Women who found vaginal estrogen creams or rings logistically difficult and want an insert format
• Women with HSDD (hypoactive sexual desire disorder) in addition to GSM, since the testosterone metabolite produced locally may support desire. The REJOICE-2 trial data showed improvement in multiple sexual function domains beyond just pain.

Women who should discuss carefully before starting

• Women with current or past estrogen-receptor-positive breast cancer: get oncology clearance
• Women who drink more than 7 standard drinks per week (the CDC threshold for heavy drinking in women): discuss the additive estrogen effect
• Perimenopausal women who are still ovulating: reliable contraception required
• Women on strong CYP3A4 inhibitors or inducers: expect possible metabolite level shifts

Women for whom Intrarosa is contraindicated

• Pregnant women: contraindicated, full stop
• Women with undiagnosed abnormal vaginal bleeding: evaluate first
• Women with known or suspected estrogen- or androgen-dependent malignancy: use requires specialist approval

The Evidence Gap: What We Don't Know

Women have been systematically under-represented in pharmacokinetic interaction studies, and this applies to the alcohol-prasterone question specifically. The REJOICE trial enrolled postmenopausal women aged 40-80, which is appropriate for the indication, but the trial did not systematically assess alcohol use as a covariate of pharmacokinetic or clinical outcomes.

No published randomized trial has compared pharmacokinetic parameters of prasterone in women who drink regularly versus abstainers. What the field knows is extrapolated from:

1. The general pharmacology of alcohol's effect on sex steroid metabolism, particularly the Ginsburg et al. NEJM 1996 findings in postmenopausal women on oral HRT.
2. The low systemic estradiol exposure established in the Intrarosa FDA pharmacokinetic review.
3. Mechanistic understanding of intracrinology and why vaginal-to-systemic conversion is buffered.

The honest answer is that no one has directly studied "Intrarosa plus alcohol." The absence of a labeled interaction is not the same as "studied and found safe in combination." For women who want certainty, none exists at this level of specificity. What exists is a reasonable pharmacological argument that the interaction is unlikely to be clinically dangerous at moderate alcohol intake, grounded in the drug's low systemic exposure profile.

Practical Guidance for Women Using Intrarosa

Insert Intrarosa at bedtime as directed. If you have a glass of wine with dinner, the timing gap between drinking and inserting means alcohol is partly cleared before the insert dissolves, which further reduces any pharmacokinetic overlap.

Avoid inserting Intrarosa and then drinking heavily before sleep. The combination of impaired sleep, transient CYP inhibition at high alcohol doses, and the general estrogen-raising effect of alcohol makes this a pattern worth avoiding, even if no catastrophic interaction results.

If you have a history of estrogen-receptor-positive breast cancer, keep alcohol under seven drinks per week. The World Cancer Research Fund / AICR evidence review consistently links alcohol dose to breast cancer risk via estrogenic pathways. Your oncologist's guidance takes precedence over any general recommendation here.

Tell every prescriber, including your gynecologist and any oncologist, about all alcohol use. Alcohol intake is a clinical variable in hormone management decisions. Underreporting it leads to suboptimal care.

If Intrarosa does not relieve dyspareunia after 12 weeks of nightly use (the duration validated in the REJOICE trial), return to your clinician. Inadequate response may reflect adherence issues, anatomical factors, or the need to add a systemic therapy.